Rapport Therapeutics to Participate in Upcoming Investor Conferences

Impact · against what's priced in

The report of a 90% median reduction in clinical seizures for RAP-219 during Phase 2a follow-up provides a strong clinical catalyst for Rapport Therapeutics. This efficacy data suggests higher potential for the lead candidate's success in treating focal onset seizures than previously established.

RAPP+0.60

No priced-in read yet

In context

The Phase 2a follow-up data showing a 90% median reduction in clinical seizures over baseline in weeks 9-12 is a material efficacy signal for the lead drug candidate RAP-219.

Read from the article alone

• clinical trials▲153%
• healthcare
• RAPP
• biotechnology
• investor conference
• neurology
• precision medicine
• psychiatry

Top 1 mover · tap to explore